Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
September 08, 2021 00:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion to Participate in Upcoming September Investment Conferences
September 02, 2021 00:20 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Angion Biomedica Corp.
-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug...
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
August 03, 2021 00:05 ET
|
Angion Biomedica Corp.
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney...
Travere Therapeutics Reports Second Quarter 2021 Financial Results
July 29, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...
Travere Therapeutics to Report Second Quarter 2021 Financial Results
July 22, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close...
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
June 04, 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high...
Travere Therapeutics to Present at Upcoming Investor Conferences
May 27, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
May 25, 2021 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS)....
Travere Therapeutics Reports First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of...